Product Portfolio Expansion
Fagron Sterile Services US is pleased to announce the continued expansion of its product portfolio in 2021. Introducing a new platform with multiple presentations available – Intravenous (IV) Bags. The new platform launches with multiple presentations of fentaNYL, HYDROmorphone, and midazolam. In the coming months, FSS will continue to expand IV Bag offerings to include oxyTOCIN, NORepinephrine and others.
Product Platform Highlights:
- Individually overwrapped for extended beyond use dating (BUD) and product protection
- Multiple concentrations, volumes, and containers available
- Latex-free, DEHP-free, and PVC-free
- Expanded offerings throughout 2021
- Download the IV Bag Launch Sheet
Download a full product catalog and set up a free consultation, or talk with your dedicated Account Representative today.
About Fagron Sterile Services
Fagron Sterile Services US (FSS), a top-tier DEA and FDA-registered 503B Outsourcing Provider, produces reliable supply of high-quality sterile medications with cGMP compliant operations for patient-focused healthcare facilities across North America.
FSS' team employs expertise in legal and regulatory compliance, pharmaceutical manufacturing and repackaging, leveraging industry leading automation, advanced environmental monitoring and sophisticated in-house quality testing labs. Batches are validated to support Beyond Use Dating (BUD) and only released after successful sterility, particulate matter and potency testing are complete.
FSS offers a broad product portfolio across Operating Room Anesthesia, Ophthalmics, Pain Management and other Specialty Presentations, and holds Integrated Delivery Network (IDN) agreements within all major GPOs.